 HOUSTON, May 14, 2021 PRNewswire -- CNS Pharmaceuticals, Inc. NASDAQ: CNSP CNS or the Company, a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system CNS, today reported its financial results for the quarter ended March 31, 2021. Additionally, the Company provided a clinical update as well as a business outlook. 